Drugs /

clag-m regimen

Back to Drugs List

Overview

NCI Definition [1]:
A chemotherapy regimen consisting of cladribine, cytarabine, filgrastim, and mitoxantrone that may be used in the treatment of acute myeloid leukemia (AML).

Clinical Trials

View Clinical Trials for clag-m regimen

Clag-m regimen has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating clag-m regimen, 1 is phase 1 (1 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).

PML-RARA Fusion, t(15;17)(q22;q12), and t(15;17)(q24;q21) are the most frequent biomarker inclusion criteria for clag-m regimen clinical trials.

Acute myeloid leukemia is the most common disease being investigated in clag-m regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Clag-M Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating clag-m regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
clag/m, clag-m, cladribine/cytarabine/filgrastim/mitoxantrone regimen, cladribine/cytarabine/filgrastim/mitoxantrone, cladribine/ara-c/g-csf/mitoxantrone, cladribine-cytarabine-filgrastim-mitoxantrone, cladarabine/ara-c/granulocyte-colony stimulating factor/mitoxantrone
NCIT ID [1]:
C161950

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.